The trading price of NewAmsterdam Pharma Company NV (NASDAQ:NAMS) closed higher on Monday, April 14, and closing at $16.42, 8.60% higher than its previous close.
Traders who pay close attention to intraday price movement should know that it fluctuated between $14.92 and $16.55. In examining the 52-week price action we see that the stock hit a 52-week high of $27.29 and a 52-week low of $14.06. Over the past month, the stock has lost -29.74% in value.
NewAmsterdam Pharma Company NV, whose market valuation is $1.80 billion at the time of this writing, is expected to release its quarterly earnings report on 2025-Feb-25. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by -0.44 per share this quarter, however they have predicted annual earnings per share of -1.73 for current year and -1.74 for next year.
From the analysts’ viewpoint, the consensus estimate for the company’s annual revenue is 15.92M.
On the technical side, indicators suggest NAMS has a 100% Sell on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 50% Sell, while an average of long term indicators suggests that the stock is currently 50% Sell.
Here is the average analyst rating on the stock as represented by 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock should be considered as either strong buy or strong sell respectively. The number of analysts that have assigned NAMS a recommendation rating is 1. Out of them, 0 rate it a Hold, while 1 recommend Buy, whereas 0 assign an Overweight rating. 0 analyst(s) have tagged NewAmsterdam Pharma Company NV (NAMS) as Underweight, while 0 advise Sell. Analysts have rated the stock Buy, likely urging investors to take advantage of the opportunity to add to their holdings of the company’s shares.
A quick review shows that NAMS’s price is currently -16.55% off the SMA20 and -19.60% off the SMA50. The RSI metric on the 14-day chart is currently showing 34.86, and weekly volatility stands at 12.12%. When measured over the past 30 days, the indicator reaches 8.35%. NewAmsterdam Pharma Company NV (NASDAQ:NAMS)’s beta value is currently sitting at 0.14, while the Average True Range indicator is currently displaying 1.57. With analysts defining $41-$48 as the low and high price targets, we arrive at a consensus price target of $45 for the trailing 12-month period. The current price is about -149.7% off the estimated low and -192.33% off the forecast high, based on this estimate. Investors will be thrilled if NAMS’s share price rises to $45, which is the median consensus price. At that level, NAMS’s share price would be -174.06% below current price.
To see how NewAmsterdam Pharma Company NV stock has been performing in comparison to its peers in the industry, here are the numbers: NAMS stock’s performance was 8.60% in the latest trading, and -17.61% in the past year.
An evaluation of the daily trading volume of NewAmsterdam Pharma Company NV (NASDAQ:NAMS) indicates that the 3-month average is 1.01 million. However, this figure has increased over the past 10 days to an average of 1.47.
Currently, records show that 108.06 million of the company’s shares remain outstanding. The insiders hold 44.40% of outstanding shares, whereas institutions hold 48.02%. The stats also highlight that short interest as of 2025-03-31, stood at 5.34 million shares, resulting in a short ratio of 4.14 at that time. From this, we can conclude that short interest is 732.00 of the company’s total outstanding shares. It is noteworthy that short shares in March were up slightly from the previous month’s figure, which was 3.04 million. However, since the stock’s price has seen -36.11% year-to-date, investors’ interest is likely to be reignited due to its potential to move even lower.
